VistaGen Therapeutics News

VistaGen Therapeutics Aktie VALOR 25212189 / ISIN US92840H2022

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

24.05.23	Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health (Businesswire)
19.04.23	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Businesswire)
06.04.23	Vistagen Receives New European Patent for AV-101 (Businesswire)
22.03.23	Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder (Businesswire)
08.03.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
02.03.23	Vistagen to Present at Cowen 43rd Annual Health Care Conference (Businesswire)
01.03.23	Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine (Businesswire)
07.02.23	Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results (Businesswire)
06.02.23	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 (Businesswire)
02.02.23	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition (Businesswire)
24.01.23	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
10.01.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety (Businesswire)
30.12.22	Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder (Businesswire)
21.12.22	Vistagen to Acquire Pherin Pharmaceuticals (Businesswire)
06.12.22	Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder (Businesswire)
30.11.22	Vistagen Receives FDA "Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder (Businesswire)
17.11.22	Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (Businesswire)
10.11.22	Vistagen Reports Second Quarter Financial Results and Provides Corporate Update (Businesswire)
04.11.22	Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022 (Businesswire)
03.11.22	Vistagen to Present at Stifel 2022 Healthcare Conference (Businesswire)
26.10.22	Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ (Businesswire)
19.10.22	Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022 (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	67.10	1.82 %	K V
Lonza Grp	559.00	0.98 %	K V
Logitech Intl	86.62	0.70 %	K V
CieFinRichemont	160.70	0.59 %	K V
Kuehne+Nagel Int	153.95	-0.23 %	K V
UBS Group	30.21	-0.23 %	K V
Swisscom	593.00	-0.25 %	K V
Alcon	59.34	-0.30 %	K V
Roche Hldg G	279.40	-1.52 %	K V